People · Operator
Named in public records as an officer, director or promoter · active 2014–2023 · Biotechnology, Other, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Morphic Holding, Inc. | — | Biotechnology | Series C | $200.6M | $1.5B | 2016 |
| RTS Holding, Inc. | — | Other | Series C | $138.3M | $128.1M | 2021 |
| Amarantus Bioscience Holdings, Inc. | — | Pharmaceuticals | Seed | $6.0M | $11.4M | 2014 |
| Kalytera Therapeutics, Inc. | — | Pharma | Pre-Seed | $2.2M | $35.9M | 2017 |
Robert Farrell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Farrell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Robert Harris | 1 | 9 |
| Bruce Rogers | 1 | 7 |
| Jerome Zeldis | 1 | 6 |
| Vikas Goyal | 1 | 5 |
| David Lowe | 1 | 5 |
| Ramy Farid | 1 | 5 |
| Robert L. Harris | 1 | 4 |
| Timothy A. Springer | 1 | 4 |
| Shazi Visram | 1 | 4 |
| Lew Frankfort | 1 | 4 |
| Timothy Springer | 1 | 3 |
| David Stefansky | 1 | 3 |
| Jeff Paley | 1 | 3 |
| Mark E Benedyk | 1 | 2 |
| Gustav Christensen | 1 | 2 |
| Iain Ross | 1 | 2 |
| Barbara Dalton | 1 | 2 |
| Marc Faerber | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.